（来源：新安晚报） 本报讯 2月12日，上海中医药大学附属曙光医院安徽医院（以下简称"上海曙光医院安徽医院"）医疗综 合楼项目主体结构顺利封顶，安徽人民在家门口享受国家级高水平中医诊疗服务的愿景，正从蓝图加速 变为现实。 上海曙光医院安徽医院医疗综合楼规划总建筑面积12.39万平方米、床位1000张，整个医疗综合大楼预 计2027年6月全面交付使用。届时，一座集门诊、住院、医技于一体的国家中医区域医疗中心将完整呈 现在安徽人民面前。 封顶是新起点，更是冲锋号。"医院综合楼项目主体按计划顺利封顶，预示着国家中医区域医疗中心建 设又取得了一个阶段性的成果。"安徽中医药大学党委常委、副校长聂久胜表示，封顶是沪皖中医药协 同发展的重要里程碑，为沪皖两地优质医疗资源的扩充和下沉做好了物质保障。"我们要将上海曙光医 院的院内制剂平移到安徽推广使用，平移医院内部管理的品牌文化和治理模式，以此来打造一个全新的 国家中医区域医疗中心。" 转自：新安晚报 作为第四批国家区域医疗中心项目之一、安徽省首个国家中医区域医疗中心，上海曙光医院安徽医院于 2023年1月正式揭牌。三年来，医院坚持"边运行边建设"，平移上海曙光医院临床三新技 ...

规定以"规范医疗机构价格行为,提高价格透明度"为核心,对医疗机构价格公示作出系统规范,将集中公示 与定向告知相结合,首次将互联网医院纳入监管范围,并要求医疗机构督促服务场所内的其他经营者明码 标价,对疫苗接种、医疗救护等特殊服务作出专门要求。据新华社 记者2月13日从市场监管总局获悉,市场监管总局会同国家卫生健康委、国家医保局、国家中医药局、中 央军委后勤保障部研究起草的《医疗机构价格公示规定(征求意见稿)》,于2月13日至3月16日向社会公开 征求意见。规定共21条,主要包括制定依据和适用范围、价格公示的内容和原则性要求,以及监督方式、 法律责任等。 ...

上海铁路客运站迎来春运客流最高峰，医疗服务也悄然升级。以"医铁联动"为抓手，推动优质医疗资源 向铁路枢纽常态化、专业化延伸，上海在全市铁路交通枢纽全域构建立体化、常态化的旅客出行健康守 护网，以专业与温度护航每一段团圆之路。 2月7日中午，铁路上海站站台上演惊险一幕：正准备搭乘K4716次列车返回四川达州老家的孙先生，在 上车前突发晕厥，意识丧失，四肢出现抽搐症状。一场春运医疗保障的实战救援迅速展开——上海市静 安区闸北中心医院铁路上海站医疗点医护人员携带急救设备在三分钟内抵达现场，经专业判断为癫痫发 作，并通过绿色通道迅速完成转运救治，孙先生生命体征恢复平稳。 2月8日凌晨，一名14岁的男孩在上海松江站落客平台突发晕厥，车站工作人员第一时间发现险情并开展 现场安抚和秩序维护，同时联动120急救力量。松江区120急救人员快速抵达现场开展专业检查与规范处 在上海南站二楼出发层重点旅客候车区内，全市首个铁路枢纽医疗门诊部——上海南站红十字医疗救护 站落地。该站点由上海市第八人民医院联合铁路上海局、市红十字会及徐汇区相关单位共同设立。它不 仅是上海首个由综合性公立医院直接运营的铁路枢纽常驻医疗点，更是全国首个实现医 ...

针对公众关注的湖北有关地方精神病医院骗保问题，调查结果今天公布。一些关键事实得以查明，一些 问题疑点得以澄清，相关责任人受到严肃处理，同时有关部门以此为警、举一反三，进一步加强医保定 点医疗机构管理。这样的依法严惩，对违法骗保行为形成了有力震慑，也引发我们进一步思考。 从百姓的朴素感受出发，精神病医院作为社会特殊需求的医疗机构，是最应该有人情味、有人文关怀的 地方。倘若成为套取资金、谋取私利的工具，甚至出现患者被殴打现象，任谁都会感到不安。关切公众 的关切，对风险隐患见事早、行动快，对违法违规行为决不姑息、发现一起查处一起，这是社会健康有 序运行的重要特点。 从"解决一个问题"到"解决一类问题"，这是今日中国自净机制的深层逻辑。必须正视的是，再成熟完备 的制度，如果缺乏刚性执行，都容易沦为稻草人。这起事件启示我们，不论什么人，都应当对法律制度 存有敬畏心。倘若每个守门人为了私利而大开方便之门、视制度为无物，其终极结果就是让每个人的利 益都受损。唯以严惩方能震慑，唯有敬畏方能知止。提升制度文明乃至社会文明的水位，有赖于每一个 人。 社会运行，有阳光普照，也可能有阳光一时没有照到的角落。有问题不可怕，直面问题、及 ...

此外，公司通过北京贝黎诗及上海美丽田园医疗健康，分别于2025年11月21日根据11月21日认购自浦发 银行认购金额为人民币7000万元;于2025年11月28日根据11月28日认购自浦发银行认购金额为人民币 1000万元;及于2025年12月30日根据12月30日认购自浦发银行认购总金额为人民币8000万元的保本理财 产品。上述所有产品于本公告日期均仍尚未到期。 美丽田园医疗健康(02373)发布公告，于2026年2月13日，为有效利用闲置资金，集团的非全资附属公司 北京贝黎诗根据2月13日认购自浦发银行认购总金额为人民币8000万元的保本理财产品。 ...

Group 1: Core Insights - UBS's in-depth research in China identifies two main industry themes for 2026: self-sufficiency and overseas expansion [1] - The research covered various sectors including technology, industrial, healthcare, consumer, and utilities, visiting over 100 companies and industry experts [1] - The report highlights a shift in investor interest, with capital goods, media entertainment, and real estate development seeing increased research focus, while semiconductor and automotive parts sectors experienced a decline [1] Group 2: Technology Sector Insights - The technology sector is a key focus, with advancements in self-sufficiency moving from isolated breakthroughs to industry-wide collaboration [2] - AI capital expenditure is expected to grow steadily in 2026, driven by strong demand for AI applications and local semiconductor production [3] - Despite uncertainties regarding H200 GPU imports, domestic supply chains are adapting through technology substitution and demand upgrades [3] Group 3: Semiconductor Developments - The localization of China's semiconductor industry is accelerating, with significant progress in advanced etching/ deposition equipment, advanced packaging, and high-end analog chips [4] - Capital expenditure for wafer fabrication equipment (WFE) is projected to grow by 10-15% annually, driven by capacity expansion in advanced logic and memory wafer fabs [4] - Domestic manufacturers anticipate a substantial increase in storage capital expenditure in 2026, aligning with a global upcycle in the storage industry [4] Group 4: Overseas Expansion Trends - Multiple industries, including industrial, biopharmaceuticals, and consumer goods, are focusing on overseas expansion as a key growth strategy [6] - In the industrial sector, overseas orders for AIDC and renewable energy storage equipment are increasing significantly [7] - The healthcare sector is also prioritizing global expansion, with biopharmaceutical companies actively pursuing international collaborations and local sales team development [9] Group 5: Key Recommendations - UBS recommends several core stocks in the technology and semiconductor sectors, including Northern Huachuang (advanced etching/ deposition), Changdian Technology (advanced packaging), and Horizon Robotics (edge AI) [5][12] - In the healthcare sector, companies like WuXi AppTec (CRO/CDMO) and 3SBio (biopharmaceuticals) are highlighted as key beneficiaries of global expansion [12] - The consumer sector sees recommendations for Jason Furniture (overseas expansion) and Leap Motor (new energy vehicles), while Gree Electric Appliances is advised to sell due to margin pressures [12] Group 6: Overall Industry Outlook - The report concludes that China's industrial development in 2026 will be characterized by a dual focus on self-sufficiency in technology and overseas expansion in various sectors [13] - The integration of these two themes is expected to enhance China's economic globalization, with technology supporting overseas expansion and vice versa [13] - Investment opportunities are identified in sectors with low crowding and improving fundamentals, as well as in high-growth areas like AI and semiconductors [13]

针对上述提问，国际医学回应称："您好，感谢您对公司的关注。公司将根据股东会确立的发展战略， 积极采取各项措施，以差异化策略构建竞争优势，努力实现经营业绩的改善提升。谢谢！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 有投资者在互动平台向国际医学提问："留给国际医学的时间确实不多了。年报即将披露，股价在5元上 下徘徊，大股东质押比例逼近80%，短期债务压顶——每一条都是悬在头顶的剑。投资者不是没耐心， 而是经不起反复'黎明前最黑暗'的安慰。医疗是长周期行业，但长周期不等于无期限烧钱，更不等于用 股东的钱为管理试错买单。" ...

Core Viewpoint - Meili Tianyuan Medical Health (02373) announced the investment of idle funds into principal-protected financial products from Pudong Development Bank, totaling RMB 80 million [1] Group 1: Investment Details - The company’s non-wholly owned subsidiary, Beijing Beilish, subscribed to a principal-protected financial product from Pudong Development Bank for a total amount of RMB 80 million on February 13, 2026 [1] - Additionally, the company, through Beijing Beilish and Shanghai Meili Tianyuan Medical Health, subscribed to several other principal-protected financial products from Pudong Development Bank, including RMB 70 million on November 21, 2025, RMB 10 million on November 28, 2025, and RMB 80 million on December 30, 2025 [1] - All the aforementioned financial products are still outstanding as of the date of the announcement [1]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [10]. Core Insights - The company has experienced a significant increase in new orders, driven by the demand for new drug research, with total new orders reaching 1.135 billion yuan in 2025, a year-on-year increase of 38.62% [5]. - The company is expected to incur a net loss attributable to shareholders of between -39.85 million yuan and -26.79 million yuan for the fiscal year 2025 [4]. - The company is in the process of acquiring a controlling stake in its subsidiary, which will enhance its capabilities in safety evaluation and clinical CRO services [9]. Summary by Sections Market Performance - The company’s stock price is currently at 57.99 yuan, with a total market capitalization of 8.2 billion yuan [1]. Order Growth - As of the end of 2025, the company’s backlog of orders increased to 1.248 billion yuan, a growth of 28.23% compared to the end of 2024 [5]. - The increase in orders is attributed to a recovery in the global and Chinese biopharmaceutical investment environment, with the healthcare sector seeing a financing amount of 122.779 billion yuan, up 46.41% year-on-year [5]. Financial Performance - The company’s net profit for Q4 2025 is projected to be between -25.06 million yuan and -12 million yuan, primarily due to the execution of low-price contracts from previous periods [6]. - The gross margin is expected to recover to over 30% as the industry’s demand and supply dynamics improve [6]. Strategic Projects - The company’s strategic project in Nantong has successfully launched, covering an area of 24,000 square meters and planning to build 130 international standard animal rooms [7]. - The Shanghai project is expected to complete its construction by Q1 2026, significantly enhancing the company’s order capacity [7]. Acquisition and Collaboration - The acquisition of the subsidiary will facilitate the integration of safety evaluation and clinical CRO services, creating a comprehensive service solution [9]. - The company has established a strategic partnership with YaoKang Bio to explore joint international pathways for animal and drug evaluation [9]. Earnings Forecast - Revenue projections for 2025, 2026, and 2027 are estimated at 792 million yuan, 1.098 billion yuan, and 1.402 billion yuan, respectively, with corresponding EPS of -0.23 yuan, 0.90 yuan, and 1.63 yuan [10].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [10] Core Insights - The company expects a significant increase in new orders driven by the demand for new drug research, with total new orders reaching 1.135 billion yuan in 2025, a year-on-year increase of 38.62% [5] - The company is set to recover from previous losses, with a projected net profit range for 2025 of -39.85 million to -26.79 million yuan, influenced by the execution of low-price contracts from prior periods [4][6] - The company is expanding its capacity with strategic projects, including a new facility in Nantong and ongoing construction in Shanghai, which will enhance its order-taking capabilities [7][9] Summary by Sections Financial Performance - The company reported a net profit of 5.52 million yuan in Q1 2025, a loss of 20.71 million yuan in Q2, and a profit of 0.40 million yuan in Q3, with an expected Q4 net profit ranging from -25.06 million to -12.00 million yuan [6] - The total revenue forecast for 2025-2027 is 792 million, 1.098 billion, and 1.402 billion yuan respectively, with EPS projected at -0.23, 0.90, and 1.63 yuan [10][12] Market Dynamics - The company is benefiting from a recovering investment environment in the biopharmaceutical sector, with a 46.41% year-on-year increase in financing in the healthcare sector, amounting to 122.779 billion yuan in 2025 [5] - The company has also strengthened its overseas market presence, with new orders from international markets totaling 74.772 million yuan, accounting for 6.59% of total orders [5] Strategic Initiatives - The company plans to acquire a controlling stake in its subsidiary, Yilin Si, which will enhance its capabilities in safety evaluation and clinical research, creating an integrated service solution [9] - A strategic partnership was established with YaoKang Bio in November 2025 to explore joint international pathways for animal testing and drug evaluation [9]